- $653.01m
- $337.83m
- $63.53m
- 44
- 17
- 75
- 42
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.77 | ||
| Price to Tang. Book | 1.77 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 10.28 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -40.78% | ||
| Return on Equity | -37.76% | ||
| Operating Margin | -299.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 10.68 | 31.43 | 55.85 | 96.3 | 63.53 | 4.2 | 2.92 | 68.05% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
Directors
- William Rastetter NEC (73)
- John Wolchko PRE (50)
- John Mendlein NVC (61)
- Edward Dulac CFO (46)
- Yu-Waye Chu SVP (53)
- Mark Plavsic CTO
- Cindy Tahl GCN (48)
- Bahram Valamehr OTH (44)
- Shefali Agarwal IND (47)
- Timothy Coughlin IND (54)
- Robert Epstein IND (66)
- Robert Hershberg IND (57)
- Karin Jooss IND (56)
- Michael Lee IND (42)
- Xu Yuan IND (52)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 27th, 2007
- Public Since
- October 1st, 2013
- No. of Shareholders
- 19
- No. of Employees
- 181
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 113,172,530
- Address
- 12278 Scripps Summit Drive, SAN DIEGO, 92131
- Web
- https://fatetherapeutics.com/
- Phone
- +1 8588751803
- Auditors
- Ernst & Young LLP
Upcoming Events for FATE
Fate Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Fate Therapeutics Inc Earnings Release
Similar to FATE
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Fate Therapeutics share price?
As of Today at 19:08 UTC, shares in Fate Therapeutics are trading at $5.77. This share price information is delayed by 15 minutes.
How has the Fate Therapeutics share price performed this year?
Shares in Fate Therapeutics last closed at $5.77 and the price had moved by -6.94% over the past 365 days. In terms of relative price strength the Fate Therapeutics share price has underperformed the S&P500 Index by -24.84% over the past year.
What are the analyst and broker recommendations for Fate Therapeutics?
The overall consensus recommendation for Fate Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Fate Therapeutics dividend yield?
Fate Therapeutics does not currently pay a dividend.
Does Fate Therapeutics pay a dividend?
Fate Therapeutics does not currently pay a dividend.
When does Fate Therapeutics next pay dividends?
Fate Therapeutics does not currently pay a dividend.
How do I buy Fate Therapeutics shares?
To buy shares in Fate Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Fate Therapeutics?
As of the previous close price of $5.77, shares in Fate Therapeutics had a market capitalisation of $653.01m.
Where are Fate Therapeutics shares listed?
Here are the trading details for Fate Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: FATE
What kind of share is Fate Therapeutics?
Based on an overall assessment of its quality, value and momentum Fate Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Fate Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Fate Therapeutics is $7.80. That is 35.18% above the last closing price of $5.77.
Analysts covering Fate Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.96 for the next financial year.
What is the trend in the Fate Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fate Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +189.74%.
As of the last closing price of $5.77, shares in Fate Therapeutics were trading +41.48% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Fate Therapeutics PE Ratio?
The Fate Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.77.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Fate Therapeutics?
Fate Therapeutics' management team is headed by:
- William Rastetter - NEC
- John Wolchko - PRE
- John Mendlein - NVC
- Edward Dulac - CFO
- Yu-Waye Chu - SVP
- Mark Plavsic - CTO
- Cindy Tahl - GCN
- Bahram Valamehr - OTH
- Shefali Agarwal - IND
- Timothy Coughlin - IND
- Robert Epstein - IND
- Robert Hershberg - IND
- Karin Jooss - IND
- Michael Lee - IND
- Xu Yuan - IND